If I’d put £10,000 into the FTSE 100’s biggest stock at the start of 2024, here’s what I’d have now

The FTSE 100’s biggest company has romped away from the index over the last five years, but has fallen behind in 2024. Is it time for me to buy?

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The value of the FTSE 100 is heavily influenced by its largest members. This made me wonder how closely the largest company in the FTSE tracks the overall value of the index.

Can investors in the biggest stocks still beat the market by picking shares carefully?

It turns out that they can – at least sometimes.

Letting winners run

The biggest company in the FTSE 100 is pharmaceutical group AstraZeneca (LSE: AZN), with a market cap of £174bn.

In second and third place are Shell (£154bn) and HSBC Holdings (£128bn).

This picture has changed significantly over the last five years.

At the start of November 2019, Shell topped the leaderboard with a market cap of £187bn, while HSBC was almost unchanged at £125bn.

AstraZeneca was well down the list with a market cap of £97bn, but the pharmaceutical company’s share price has risen by almost 50% over the last five years. This has allowed it to romp away from the FTSE 100, up by just 11% over the same period.

2024 slowdown

AstraZeneca’s strong run of growth has been well deserved, in my view. Annual sales have doubled to $49bn since 2019, while operating profit has risen threefold to $9bn.

However, since hitting a record high of 13,388p earlier this year, the share price has fallen by over 15% to around 11,000p.

This slump means that the shares are now only 3.5% higher than they were at the start of this year.

Including some dividends, I reckon AstraZeneca shareholders have had a total return of about 6% this year. An investment of £10,000 on 2 January would now be worth about £10,600.

This rather average result means the company has lagged behind the FTSE 100, which has delivered a total return of about 8% so far in 2024.

What next for AstraZeneca?

Broker forecasts for the company’s 2024 earnings have slipped slightly this year. But City analysts are still confident the group’s profits will rise by around 15% in 2025.

Looking ahead to 2026, consensus estimates suggest earnings will rise by a further 12%.

These forecasts seem encouraging to me. However, my main concern with AstraZeneca (and other pharmaceuticals) is that future performance is very hard to predict.

These businesses depend on a regular supply of new medicines, but developing these takes years and is very expensive. A lot of money must be spent before new treatments can be trialled, They’re not always successful.

For example, AstraZeneca reported disappointing trial results for two new cancer treatments in September. That could limit their future sales and make regulatory approval more difficult.

Should I buy now?

AstraZeneca’s share price slump has left the stock trading on a 2024 forecast price-to-earnings (P/E) ratio of 18, falling to 15 in 2025.

Although the dividend yield is relatively low at 2.1%, I don’t think the shares look too expensive for a leading global pharma business.

However, the uncertainty I’ve mentioned above means that I’d prefer to have a greater margin of safety when buying this stock. AstraZeneca will stay on my watch list for now, in hope of a cheaper entry point.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and HSBC Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »

Investing Articles

The JD Sports Fashion share price has just plunged another 16%! Buy or sell?

Harvey Jones is reeling after another sharp drop in the JD Sports Fashion share price. Should he seize the chance…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

This once-great FTSE 250 UK fashion retailer is down 47%, so is it time for me to buy?

A formerly iconic UK fashion brand, this FTSE 250 firm has fallen out of favour. But it has a new…

Read more »

Investing Articles

Nvidia share price dips despite strong Q3 results. What can we expect now?

Despite posting strong Q3 results after yesterday's market close, the Nvidia share price slipped 2.5% in aftermarket trading. Mark Hartley…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

An outstanding interim report sends the Halma share price surging 10%

News of 13% revenue growth and a 17% increase in earnings per share has the Halma share price rising. And…

Read more »